BSD Medical Corporation Announces Changes to Its Board of Directors

SALT LAKE CITY, Feb. 9, 2015 (GLOBE NEWSWIRE) -- BSD Medical Corporation BSDM (Company or BSD), a leading provider of medical systems that utilize heat therapy to treat cancer, today announced the resignation of Gerhard W. Sennewald, Ph.D., and Douglas P. Boyd, Ph.D., as members of the Board of Directors. Mr. Boyd's resignation was effective on January 28, 2015 and Mr. Sennewald's resignation was effective February 4, 2015.

"With our changing product focus, we are seeking new independent directors with vast life science and commercialization success," said Timothy C. McQuay, Chairman of BSD Medical. "The Board is deeply grateful to Gerhard and Douglas for their significant contributions and outstanding service throughout their long tenure with BSD Medical. Their passion, guidance, leadership, and relentless focus have helped establish BSD as a leader in heat based cancer treatment therapies. We wish Gerhard and Douglas the best in all their future endeavors."

About BSD Medical Corporation

BSD Medical Corporation develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy, which is delivered using focused radiofrequency (RF) and microwave energy. BSD's product lines include both hyperthermia and ablation treatment systems. BSD's MicroThermX^® microwave ablation system has been developed as a stand-alone therapy to employ precision-guided microwave energy to ablate (destroy) soft tissue. The Company has developed extensive intellectual property, multiple products in the market and established distribution in the United States, Europe and Asia. Certain of the Company's products have received regulatory approvals and clearances in the United States, Europe and China.

For further information visit BSD Medical's website at www.BSDMedical.com.

Forward-Looking Statements

Statements contained in this press release that are not historical facts, including statements relating to our intent to divest our hyperthermia business in Spring 2015, focus on microwave ablation to create stockholder value, comply with Nasdaq continued listing requirements, generate capital from a transaction related to our building and pursue other strategic plans are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to risks and uncertainties, including the risk that for a variety of reasons we may not be able to execute on our strategic plans, and other risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission These forward-looking statements speak only as of the date on which such statements are made, and the Company undertakes no obligation to update such statements to reflect events or circumstances arising after such date, except as required by law.